SV

Street Verdict

Analyst Scorecard

SANOFICONR · NSE

Sanofi Consumer Healthcare India Limited

₹3,442.4

-1.49% (-₹52.1)

Prev. close

₹3,494.5

Volume

4,811

Delivery %

56.5%

As of

20 Nov 2026

Price history

₹3,442.4-₹894.2 (-20.62%) · 3M
18 Aug 2026 → 20 Nov 2026
3,4003,6003,8004,0004,20018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts are split

1 analyst stance · last 90 days · one per analyst

Trackable

none in range

Long-Horizon

none in range

Commentary

1 · 0 bull / 1 neutral / 0 bear

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 0% (0)Neutral 100% (1)Bearish 0% (0)
Explore by date range →

Analyst opinions

No trackable analyst calls on Sanofi Consumer Healthcare India Limited yet.
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Sanofi Consumer Healthcare India Limited

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.

Details

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Himanshu Bakshi

Headquarters

Mumbai

Employees

597

Key stats

Market cap

₹8,009.03 Cr

P/E ratio (TTM)

28.6

Dividend yield

2.15%

EPS (TTM)

₹121.44

Beta (1Y · daily vs NIFTY 50)

0.56

Shares float

65.73 L

EPS · quarter ended Sept 2026

₹33.26

Financial Performance

01 · Financials

0 Cr250 Cr500 Cr750 Cr1000 Cr₹0%10%20%30%40%Dec 2023Dec 2024Dec 2025
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

050100150₹Dec 2023Dec 2024Dec 2025

03 · Dividend Profile

0255075₹0%0.5%1%1.5%2%17 Apr 2519 Jun 26
Dividend (₹/share)Annualised yield

Growth compares completed fiscal-year dividend totals on the company's own calendar: January–December (calendar year — this company reports on a December year-end), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-100%0%100%200%Dec 2024Dec 2025
SalesFixed assetsTrade receivablesInventory

Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY24 (+1260%).

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr200 Cr400 Cr600 Cr₹0×0.5×1×1.5×2×Dec 2023Dec 2024Dec 2025
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr200 Cr400 Cr600 Cr₹Dec 2023Dec 2024Dec 2025
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-250 Cr0 Cr250 Cr500 Cr₹Dec 2023Dec 2024Dec 2025
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemDec 2023Dec 2024Dec 2025
₹544.30 Cr₹724.50 Cr₹878.40 Cr
EBITDA
₹221.30 Cr₹255.20 Cr₹334.00 Cr
₹164.90 Cr₹181.00 Cr₹240.10 Cr
Diluted EPS
₹71.6₹78.59₹104.27

Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemDec 2023Dec 2024Dec 2025
₹345.40 Cr₹431.30 Cr₹547.00 Cr
₹0₹20.30 Cr₹24.80 Cr
Stockholders' equity
₹207.60 Cr₹273.00 Cr₹384.00 Cr

CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemDec 2023Dec 2024Dec 2025
₹-40.00 L₹439.00 Cr₹174.80 Cr
Investing cash flow
₹0₹1.90 Cr₹-7.60 Cr
₹2.00 Cr₹-115.60 Cr₹-134.50 Cr
Capital expenditure
₹-4.00 Cr₹-9.90 Cr₹-7.60 Cr
End cash position
₹1.60 Cr₹326.90 Cr₹374.80 Cr

Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 24–Mar 25(5Q)Jun 25–Jun 26(5Q)
Promoter60.40%71.27%
Public39.60%28.73%
Employee trusts0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Sanofi Consumer Healthcare India Limited₹8,062.76 Cr₹3,472.628.821.0062.5%0.06+22.6%-28.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

SANOFICONR

Sanofi Consumer Healthcare Q3 results: Profit rises 22% to ₹77 crore as revenue grows 12%

Sanofi Consumer Healthcare India reported a 22.2% rise in consolidated profit to ₹77 crore for the September quarter, with revenue from operations growing 12.4% to ₹263 crore. This growth was driven by higher volumes and market share gains across key brands. Domestic sales increased by 19% year-on-year.

25 days ago·Read at CNBC TV18
SANOFICONR

Medico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month

The Economic Times · 2 months ago